by admin | May 5, 2025 | News
We are pleased to announce that Exogenus Therapeutics has been granted another patent, now in Europe! This is the fifth region to recognize the patent family titled “Use of umbilical cord blood-derived exosomes for tissue repair.” This patent family has also been...
by admin | Mar 11, 2025 | News
Lonza to develop a GMP-compliant process for Exo-101 manufacturing from its Siena (IT) site Exo-101 has shown safety and efficacy in multiple pre-clinical trials, and is expected to reach patients in 2027 Basel, Switzerland and Cantanhede, Portugal, 11 March 2025 –...
by admin | Sep 11, 2024 | News
We are pleased to announce that ExogenusTherapeutics has been granted another patent in Japan! This is the second patent granted in this region, and the first one to be granted within the family entitled “Compositions comprising small extracellular vesicles...
by admin | Jun 5, 2024 | News
Joana Correia, Founder and CEO of Exogenus Therapeutics, will be a featured speaker at Exosomes Europe, taking place in London on June 5th and 6th. Joana will present a talk titled “Extracellular vesicles in human health: opportunities and challenges,”...
by admin | Apr 24, 2024 | News
Exogenus Therapeutics is proud to announce a strategic investment led by 3xP Global. This funding of 3xP Global will significantly advance the development of Exogenus lead product, Exo-101, that derived from umbilical cord blood cells and has shown promise in multiple...
by admin | Dec 13, 2022 | News
Exogenus Therapeutics CEO, Joana Simões Correia, participated in a roundtable organized by Cell & Gene Therapy Insights and Miltenyi, as part of a discussion panel about “Diagnostic & therapeutic uses for extracellular vesicles (EVs): insights into a rapidly...
